Health Catalyst Inc (HCAT)
Official siteHEALTHCARE • HEALTH INFORMATION SERVICES • NASDAQ
Market Cap: $115.00M
Last updated: Nov 17, 2026 at 11:05 AM ET
Health Catalyst Inc (HCAT) Financials: Revenue, Profit and Cash Flow
Health Catalyst reported revenue of $311.14M for the fiscal year ended Dec 31, 2025, up 1.5% from the year before. That year, net income was -$177.97M with a net margin of -57.2%, operating cash flow was $731.00K and free cash flow was -$237.00K. The quarter ended Sep 30, 2026 had revenue of $56.28M and net income of $40.50M.
Revenue and Margins
The operating margin was -51.7% in the fiscal year ended Dec 2025. Over the 8 years to Dec 2025, revenue grew from $73.08M, a compound annual rate of 19.9%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $311.14M | +1.5% | 48.7% | -51.7% | -57.2% |
| Dec 2024 | $306.58M | +3.6% | 45.9% | -22.8% | -22.7% |
| Dec 2023 | $295.94M | +7.1% | 44.5% | -42.9% | -39.9% |
| Dec 2022 | $276.24M | +14.2% | 48.2% | -50.7% | -49.7% |
| Dec 2021 | $241.93M | +28.1% | 48.6% | -59.4% | -63.3% |
| Dec 2020 | $188.84M | +21.9% | 48.1% | -50.9% | -60.9% |
| Dec 2019 | $154.94M | +37.6% | 51.4% | -35.4% | -38.8% |
| Dec 2018 | $112.57M | +54.0% | 46.8% | -53.4% | -55.1% |
| Dec 2017 | $73.08M | N/A | 40.3% | -62.3% | -64.4% |
Income Statement
In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, net income turned positive after a loss in the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $311.14M | $306.58M | $295.94M | $276.24M | $241.93M | $188.84M | $154.94M | $112.57M | $73.08M |
| Cost of revenue | $159.46M | $165.81M | $164.10M | $143.05M | $124.35M | $98.08M | $75.34M | $59.85M | $43.64M |
| Gross profit | $151.68M | $140.78M | $131.83M | $133.19M | $117.57M | $90.77M | $79.60M | $52.72M | $29.44M |
| Research and development | $49.77M | $57.95M | $72.63M | $75.68M | $62.73M | $53.52M | $46.25M | $38.59M | $28.47M |
| Operating income | -$160.85M | -$69.81M | -$126.90M | -$140.00M | -$143.65M | -$96.13M | -$54.87M | -$60.09M | -$45.54M |
| Net income | -$177.97M | -$69.50M | -$118.15M | -$137.40M | -$153.21M | -$115.02M | -$60.10M | -$61.98M | -$47.03M |
| EBITDA | -$108.19M | -$29.88M | -$92.88M | -$92.44M | -$92.97M | -$68.00M | -$45.19M | -$52.29M | -$39.75M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $56.28M | $70.49M | $70.76M | $74.68M | $76.32M | $80.72M | $79.41M | $79.61M | $76.35M | $75.90M | $74.72M | $75.08M |
| Gross profit | $24.04M | $34.86M | $35.46M | $39.38M | $37.82M | $38.24M | $36.23M | $34.69M | $34.04M | $35.84M | $36.21M | $30.51M |
| Operating income | $50.14M | -$36.48M | -$106.48M | -$86.08M | -$17.51M | -$37.09M | -$20.17M | -$17.50M | -$13.69M | -$15.81M | -$22.81M | -$32.78M |
| Net income | $40.50M | -$40.54M | -$111.03M | -$91.03M | -$22.23M | -$40.98M | -$23.74M | -$20.67M | -$14.73M | -$13.52M | -$20.59M | -$30.31M |
Balance Sheet
As of Dec 2025, total debt of $153.25M exceeded cash and equivalents by $102.44M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Total assets | $502.64M | $858.93M | $701.81M | $752.29M | $832.10M | $577.74M | $302.36M | $110.97M | $110.27M |
| Current assets | $169.31M | $465.65M | $393.40M | $427.80M | $508.39M | $329.80M | $264.24M | $66.86M | $71.39M |
| Cash and equivalents | $50.81M | $249.65M | $106.28M | $116.31M | $193.23M | $91.95M | $18.03M | $28.43M | $22.98M |
| Total liabilities | $256.86M | $493.72M | $334.89M | $327.28M | $310.00M | $301.64M | $101.72M | $75.90M | $369.74M |
| Short-term debt | $1.63M | $231.18M | $0 | $3.43M | $4.58M | $14.43M | $0 | $3.46M | $2.13M |
| Long-term debt | $151.62M | $151.18M | $228.03M | $226.52M | $180.94M | $168.99M | $48.20M | $18.81M | $9.62M |
| Shareholder equity | $245.78M | $365.21M | $366.92M | $425.01M | $522.10M | $276.10M | $200.64M | -$374.77M | -$259.48M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $237.42M | $358.60M | $412.20M | $502.64M | $587.13M | $616.18M | $891.54M | $858.93M | $813.05M | $691.72M | $695.11M | $701.81M |
| Total liabilities | $91.83M | $257.78M | $274.06M | $256.86M | $255.21M | $268.63M | $514.73M | $493.72M | $458.01M | $334.72M | $337.90M | $334.89M |
| Cash and equivalents | $53.75M | $60.59M | $59.86M | $50.81M | $40.30M | $50.71M | $341.97M | $249.65M | $328.33M | $201.90M | $201.37M | $106.28M |
| Shareholder equity | $145.59M | $100.83M | $138.15M | $245.78M | $331.92M | $347.55M | $376.81M | $365.21M | $355.04M | $357.00M | $357.21M | $366.92M |
Cash Flow
In the fiscal year ended Dec 2025, capital expenditures exceeded operating cash flow, leaving negative free cash flow.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $731.00K | $14.56M | -$33.08M | -$35.27M | -$23.12M | -$26.15M | -$32.18M | -$40.30M | -$36.83M |
| Capital expenditures | $968.00K | $1.62M | $1.24M | $2.17M | $10.45M | $7.78M | $2.02M | $2.08M | $3.34M |
| Free cash flow | -$237.00K | $12.94M | -$34.32M | -$37.44M | -$33.57M | -$33.92M | -$34.20M | -$42.37M | -$40.17M |
| Share repurchases | $5.00M | $0 | $1.81M | $8.39M | $0 | $0 | $4.61M | $8.71M | N/A |
| Investing cash flow | $36.19M | -$22.90M | $20.29M | -$39.02M | -$139.68M | -$82.56M | -$209.60M | $21.40M | $22.41M |
| Financing cash flow | -$235.78M | $151.75M | $2.73M | -$2.61M | $264.08M | $182.61M | $231.38M | $24.35M | $24.87M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$1.88M | $275.00K | $18.51M | $9.91M | -$464.00K | -$9.00M | $280.00K | -$3.53M | $6.21M | $1.61M | $10.27M | -$19.04M |
| Capital expenditures | $156.00K | $345.00K | $338.00K | $273.00K | $255.00K | $230.00K | $670.00K | $413.00K | $705.00K | $290.00K | $208.00K | $255.00K |
| Free cash flow | -$2.03M | -$70.00K | $18.17M | $9.64M | -$719.00K | -$9.23M | -$390.00K | -$3.94M | $5.50M | $1.32M | $10.06M | -$19.30M |
Frequently Asked Questions About HCAT
What is Health Catalyst's annual revenue?
Health Catalyst reported revenue of $311.14M for the fiscal year ended Dec 31, 2025.
How fast is Health Catalyst's revenue growing?
Revenue was up 1.5% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 4.0%.
Is Health Catalyst profitable?
No. Health Catalyst reported net income of -$177.97M for the fiscal year ended Dec 31, 2025, with a net margin of -57.2%.
How much free cash flow does HCAT generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $731.00K minus capital expenditures of $968.00K produced free cash flow of -$237.00K.
How much debt does Health Catalyst have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $151.62M, short-term debt of $1.63M and cash and equivalents of $50.81M.
HCAT pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors